Skip to main content
Explore URMC
menu

Dementia With Lewy Bodies: Effects of the drug Neflamapimod on cognition (thought processes)

Research Question:
What are the effects of the drug, Neflamapimod, in participants with Lewy Body Dementia?

Basic Study Information

Purpose:
This is a study of neflamapimod versus placebo . It will be administered with food for 16 weeks in participants with Dementia With Lewy Bodies. The primary objective is to evaluate the effect of neflamapimod on cognitive function (thought processes).

Location: University of Rochester
Study Reference #: RSRB# SITE000182

Lead Researcher (Principal Investigator)

Lead Researcher: Katherine Amodeo

Study Contact Information

Study Coordinator: Nicole Guerrero
Phone: (585) 341-7579
Email: nicole_guerrero@URMC.Rochester.edu

Additional Study Details

Study Details:
This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB. The primary objective is to evaluate the effect of neflamapimod on cognitive function as assessed in a study-specific Cogstate Neuropsychological Test Battery (NTB). Secondary endpoints include the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB), Mini-Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI-10), Timed Up and Go Test, and electroencephalogram (EEG) as a potential biomarker for DLB.

Number of Visits:  6 to 10
Parking:  Free
Reimbursement:  Yes

Learn More About These Conditions

More information about Dementia

More information about Lewy Body Disease

Return to Search